middle.news

AdAlta strengthens EW-001's US pathway with orphan designation

8:28am on Tuesday 17th of November, 2026 AEDT • Biotechnology
Read Story

AdAlta strengthens EW-001's US pathway with orphan designation

8:28am on Tuesday 17th of November, 2026 AEDT
Key Points
  • US orphan designation assigned to AdAlta by Shanghai Cell Therapy Group
  • Potential seven-year US exclusivity applies only if EW-001 is approved
  • FDA pre-IND meeting supported using data from multiple manufacturing variants
  • Australian manufacturing run scheduled for December 2026
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about AdAlta (ASX:1AD)
OPEN ARTICLE